IL202659A0 - Fused thiazole derivatives as kinase inhibitors - Google Patents

Fused thiazole derivatives as kinase inhibitors

Info

Publication number
IL202659A0
IL202659A0 IL202659A IL20265909A IL202659A0 IL 202659 A0 IL202659 A0 IL 202659A0 IL 202659 A IL202659 A IL 202659A IL 20265909 A IL20265909 A IL 20265909A IL 202659 A0 IL202659 A0 IL 202659A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
thiazole derivatives
fused thiazole
substituted
derivatives
Prior art date
Application number
IL202659A
Other languages
English (en)
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Priority claimed from PCT/GB2008/002194 external-priority patent/WO2009001089A1/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of IL202659A0 publication Critical patent/IL202659A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL202659A 2006-06-26 2009-12-10 Fused thiazole derivatives as kinase inhibitors IL202659A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors
PCT/GB2008/002194 WO2009001089A1 (en) 2007-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL202659A0 true IL202659A0 (en) 2010-06-30

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202659A IL202659A0 (en) 2006-06-26 2009-12-10 Fused thiazole derivatives as kinase inhibitors

Country Status (20)

Country Link
US (3) US8242116B2 (OSRAM)
EP (2) EP2035436B1 (OSRAM)
CN (1) CN101687885B (OSRAM)
AT (1) ATE510840T1 (OSRAM)
AU (1) AU2008269577B2 (OSRAM)
CA (1) CA2692085C (OSRAM)
CO (1) CO6270229A2 (OSRAM)
CY (1) CY1114419T1 (OSRAM)
DK (1) DK2170906T3 (OSRAM)
EA (1) EA017187B1 (OSRAM)
ES (2) ES2365258T3 (OSRAM)
HR (1) HRP20130523T1 (OSRAM)
IL (1) IL202659A0 (OSRAM)
ME (1) ME01592B (OSRAM)
MX (1) MX2009013740A (OSRAM)
MY (1) MY148852A (OSRAM)
PL (1) PL2170906T3 (OSRAM)
PT (1) PT2170906E (OSRAM)
RS (1) RS52824B (OSRAM)
WO (1) WO2008001076A1 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US8603945B2 (en) * 2008-07-23 2013-12-10 The Regents Of The University Of California Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants
WO2010027002A1 (ja) * 2008-09-05 2010-03-11 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
AU2010216219A1 (en) 2009-02-17 2011-09-01 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
WO2010107765A1 (en) * 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5554833B2 (ja) * 2009-05-20 2014-07-23 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
EP2467387B1 (en) 2009-08-20 2015-01-07 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
WO2011073347A1 (en) * 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
BR112012014436A2 (pt) 2009-12-18 2019-09-24 Janssen Pharmaceutica Nv tiazóis bicíclicos como moduladores alostéricos de receptores mglur5
MX2012014575A (es) 2010-06-15 2013-02-07 Bayer Ip Gmbh Nuevos derivados de arilamida orto-sustituidos.
BR112013007056A2 (pt) 2010-10-01 2019-09-24 Basf Se compostos de imina
WO2012051410A2 (en) * 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2011332859A1 (en) * 2010-11-24 2013-06-20 Exelixis, Inc. Benzoxazepines as inhibitors of mTOR and methods of their use and manufacture
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
MX2013010871A (es) 2011-03-23 2014-01-31 Amgen Inc Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
PT2794600T (pt) 2011-12-22 2018-03-13 Novartis Ag Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
US8952026B2 (en) 2013-03-14 2015-02-10 Epizyme, Inc. PRMT1 inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
KR102325919B1 (ko) * 2013-10-21 2021-11-12 우미코레 아게 운트 코 카게 방향족 아민의 모노아릴화
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
US20220202824A1 (en) 2018-09-13 2022-06-30 Stemline Therapeutics, Inc. Methods for Treating Centronuclear Myopathy
KR20210108416A (ko) 2018-12-19 2021-09-02 레오 파마 에이/에스 Il-17의 소분자 조절제로서의 아미노산 아닐라이드
TWI834795B (zh) * 2019-01-08 2024-03-11 日商杏林製藥股份有限公司 15-pgdh抑制劑
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
CN101687885B (zh) 2012-08-22
AU2008269577A1 (en) 2008-12-31
EA201000038A1 (ru) 2010-06-30
WO2008001076A1 (en) 2008-01-03
EA017187B1 (ru) 2012-10-30
EP2170906A1 (en) 2010-04-07
US20110003785A1 (en) 2011-01-06
MX2009013740A (es) 2010-02-01
US8242116B2 (en) 2012-08-14
US20100137302A1 (en) 2010-06-03
ME01592B (me) 2014-09-20
US20130079330A1 (en) 2013-03-28
DK2170906T3 (da) 2013-06-24
CN101687885A (zh) 2010-03-31
HRP20130523T1 (en) 2013-07-31
PT2170906E (pt) 2013-06-25
EP2035436A1 (en) 2009-03-18
CO6270229A2 (es) 2011-04-20
PL2170906T3 (pl) 2013-08-30
MY148852A (en) 2013-06-14
ES2416364T3 (es) 2013-07-31
CA2692085C (en) 2015-10-13
ES2365258T3 (es) 2011-09-27
EP2170906B1 (en) 2013-04-03
ATE510840T1 (de) 2011-06-15
EP2035436B1 (en) 2011-05-25
US8710054B2 (en) 2014-04-29
CA2692085A1 (en) 2008-12-31
RS52824B (OSRAM) 2013-10-31
CY1114419T1 (el) 2016-08-31
AU2008269577B2 (en) 2012-12-20
US8338592B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
IL202659A0 (en) Fused thiazole derivatives as kinase inhibitors
GB0508471D0 (en) Therapeutic agents
MY146387A (en) Thieno-pyridine derivatives as mek inhibitors
WO2009081105A3 (en) Quinoxaline and quinoline derivatives as kinase inhibitors
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
WO2010052448A3 (en) Fused pyrazine derivatives as kinase inhibitors
NO20081133L (no) Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
SMT201600089B (it) Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt
EP3489238B8 (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
TN2018000416A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
ZA201106599B (en) Pyrrolo [2,3-b] pyridine derivatives for the inhibition of raf kinases
NO20060279L (no) Thienopyridonderivater som kinaseinhibitorer
WO2006098961A3 (en) Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
IL181387A0 (en) Fused tricyclic derivatives for the treatment of psychotic disorders
ZA201100437B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors
UA99469C2 (ru) Конденсированные производные тиазола как ингибиторы киназы
SG11202100338PA (en) Imidazo[1,2-b]pyridazines as trk inhibitors
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
EP2490693A4 (en) Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
DOP2009000289A (es) Derivados de tiazol fusionados como inhibidores de quinasa
DK1784403T3 (da) Pyrrolo[3,2-b]pyridinderivater samt fremgangsmåder til deres fremstilling
HK40055110A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40055108A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40064762A (en) Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
MX2019013518A (es) Formas cristalinas de seletalisib.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed